<SEC-DOCUMENT>0001193125-20-248531.txt : 20200918
<SEC-HEADER>0001193125-20-248531.hdr.sgml : 20200918
<ACCEPTANCE-DATETIME>20200918060814
ACCESSION NUMBER:		0001193125-20-248531
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20200918
FILED AS OF DATE:		20200918
DATE AS OF CHANGE:		20200918

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			KAZIA THERAPEUTICS LTD
		CENTRAL INDEX KEY:			0001075880
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-29962
		FILM NUMBER:		201182726

	BUSINESS ADDRESS:	
		STREET 1:		LEVEL 5
		STREET 2:		20 GEORGE STREET
		CITY:			HORNSBY NSW
		STATE:			C3
		ZIP:			2077
		BUSINESS PHONE:		01161298780088

	MAIL ADDRESS:	
		STREET 1:		LEVEL 5
		STREET 2:		20 GEORGE STREET
		CITY:			HORNSBY NSW
		STATE:			C3
		ZIP:			2077

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NOVOGEN LTD
		DATE OF NAME CHANGE:	19981228
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d183941d6k.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML><HEAD>
<TITLE>FORM 6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.25in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>Form 6-K
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>REPORT OF FOREIGN PRIVATE ISSUER </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO RULE 13a-16 OR 15d-16 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>For the month of September, 2020 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>Kazia
Therapeutics Limited </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Translation of registrant&#146;s name into English) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Three International Towers Level 24 300 Barangaroo Avenue Sydney NSW 2000 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive office) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether
the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form
20-F&nbsp;&nbsp;&#9745;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Form 40-F&nbsp;&nbsp; &#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if
the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note</B>: Regulation S-T Rule
101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by
check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note</B>:
Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which
the registrant is incorporated, domiciled or legally organized (the registrant&#146;s &#147;home country&#148;), or under the rules of the home country exchange on which the registrant&#146;s securities are traded, as long as the report or other
document is not a press release, is not required to be and has not been distributed to the registrant&#146;s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on
EDGAR. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant by furnishing the information contained in this form is also thereby furnishing the information to the
Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934. Yes&nbsp;&nbsp;&#9744;&nbsp;&nbsp;&nbsp;&nbsp; No&nbsp;&nbsp;&#9745; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If
&#147;yes&#148; is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b) </P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.25in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Kazia Therapeutics Limited</B> <B></B>(Registrant) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Kate Hill </U></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Kate Hill </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Company Secretary </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date 18 September 2020 </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.25in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g183941img001.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ASX RELEASE </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">18&nbsp;September 2020 </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CLOSING DATE FOR
RECEIPT OF DIRECTOR NOMINATIONS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Sydney, </B><B>18 September 2020</B> &#150; Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian
oncology-focused biotechnology company, is pleased to advise that the Annual General Meeting of the Company will be held on <B>Friday 6&nbsp;November 2020</B>. The specific time and other details relating to the meeting will be advised in the Notice
of Meeting to be sent to shareholders and released to ASX in due course. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In accordance with ASX Listing Rules, valid nominations for the position of
director are required to be lodged at the registered office of the Company by <B>5.00&nbsp;pm (AEST) 25&nbsp;September 2020.</B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B></B>[ENDS]<B> </B></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Kazia
Therapeutics Limited</B> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Kazia Therapeutics Limited (ASX: KZA, NASDAQ: KZIA) is an innovative oncology-focused biotechnology company, based in Sydney,
Australia. Our pipeline includes two clinical-stage drug development candidates, and we are working to develop therapies across a range of oncology indications. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our lead program is paxalisib (formerly GDC-0084), a small molecule inhibitor of the PI3K / AKT / mTOR pathway, which is being developed to treat
glioblastoma, the most common and most aggressive form of primary brain cancer in adults. Licensed from Genentech in late 2016, paxalisib entered a phase II clinical trial in 2018. Interim data was reported most recently at AACR in June 2020, and
further data is expected in 2H 2020. Four additional studies are ongoing in other forms of brain cancer. Paxalisib was granted Orphan Drug Designation for glioblastoma by the US FDA in February 2018, and Fast Track Designation for glioblastoma by
the US&nbsp;FDA in August 2020. In addition, paxalisib was granted Rare Pediatric Disease Designation and Orphan Designation by the US&nbsp;FDA for DIPG in August 2020. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">TRX-E-002-1 (Cantrixil), is a third-generation benzopyran molecule with activity against cancer stem cells and is being developed to treat ovarian cancer.
TRX-E-002-1 has completed a phase I clinical trial in Australia and the United States with the final data expected in the second half of calendar 2020. Interim data was presented most recently at the AACR conference in June 2020. Cantrixil was
granted orphan designation for ovarian cancer by the US FDA in April 2015. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This document was authorized for release to the ASX by James Garner, Chief
Executive Officer, Managing Director. </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g183941img001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g183941img001.jpg
M_]C_X  02D9)1@ ! 0$"6 )8  #_X@Q824-#7U!23T9)3$4  0$   Q(3&EN
M;P(0  !M;G1R4D="(%A96B 'S@ "  D !@ Q  !A8W-P35-&5     !)14,@
M<U)'0@                  ]M8  0    #3+4A0("
M                                             !%C<')T   !4
M #-D97-C   !A    &QW='!T   !\    !1B:W!T   "!    !1R6%E:   "
M&    !1G6%E:   "+    !1B6%E:   "0    !1D;6YD   "5    '!D;61D
M   "Q    (AV=65D   #3    (9V:65W   #U    "1L=6UI   #^    !1M
M96%S   $#    "1T96-H   $,     QR5%)#   $/   " QG5%)#   $/
M" QB5%)#   $/   " QT97AT     $-O<'ER:6=H=" H8RD@,3DY."!(97=L
M971T+5!A8VMA<F0@0V]M<&%N>0  9&5S8P         2<U)'0B!)14,V,3DV
M-BTR+C$              !)S4D="($E%0S8Q.38V+3(N,0
M                                                    6%E:(
M     /-1  $    !%LQ865H@                     %A96B        !O
MH@  ./4   .06%E:(        &*9  "WA0  &-I865H@        )*    ^$
M  "VSV1E<V,         %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M    %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M                                  !D97-C         "Y)14,@-C$Y
M-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(
M     "Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M
M('-21T(                             9&5S8P         L4F5F97)E
M;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0
M    +%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR
M+C$                                  '9I97<      !.D_@ 47RX
M$,\4  /MS  $$PL  UR>     5A96B       $P)5@!0    5Q_G;65A<P
M       !                         H\    "<VEG(     !#4E0@8W5R
M=@        0     !0 *  \ %  9 !X (P H "T ,@ W #L 0 !% $H 3P!4
M %D 7@!C &@ ;0!R '< ? "! (8 BP"0 )4 F@"? *0 J0"N +( MP"\ ,$
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M])5?E<F6-):?EPJ7=9?@F$R8N)DDF9"9_)IHFM6;0INOG!R<B9SWG62=TIY
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M# P,# P,# P,#/_  !$( 'L#%P,!(@ "$0$#$0'_Q  ?   !!0$! 0$! 0
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MZ>KR\_3U]O?X^?K_V@ , P$  A$#$0 _ /A.BBBON#XL**** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M1NHHH -U&ZBB@ W4;J** /7_ -@@Y_:_\%_]=+W_ -(+FBD_8'_Y._\ !?\
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MN9=Q\K[&!FC-6-6TF[T#5;JPU"UNK&_L9GM[FVN8FAFMI48J\;HP#*ZL""I
M(((/-5ZHD,T9HHH ,T9HHH ,T9HHH ,T9HHH ,T9HHH ,T9HHH ,T9HHH ,T
M9HHH ,T9HHH ,T9HHH ,T9HHH ,T9HHH ,T9HHH ,T9HHH ,T9HHH ,T9HHH
M ,T9HHH ,T9HHH ,T9HHH ,T9HHH ,T9HHH ,T9HHH ,T9KN?@!\ ]7_ &B/
M&<NCZ3/:68M;<W5S<W)/EPQA@HX4$LQ9@ ![\C%>C_##]F32_AQ^UC8^$?B/
M-I]Q8R63WMD1.T=KJ;GB)68[2,E9/E.,M&%Y!Y[:&7UJJC)*T9.UWM<\G&9W
MA,-*=.4KSA%R<5K*R[?\/Y[:GS_FC-?2W[1'PH^%_AK]JOP;H]K-9Z7H>H%/
M[?MK:Y(@M#O(3+9/E;Q@, 1M'S<9S5W]N7X'^!_#MQX1LO!-EIUGXFUJ]%F+
M"QGW+<1/@([*6(7]X5 ;C<&;KMXZ:F458QJ2YD^1I/7>]MOO_,\^AQ1AZE3#
MT^2:]M%R3:T25]W?RZ7T:>S/ES-&:]@^/W[&'B3]GSP=9ZYJ&H:5J=E-,MM<
M?9"X:UE8$J#N W*=I&X=\<<UX_7GXC#U:$_9U59GM8''X?&4O;86:E':Z[H,
MT9HHK$[ S1FBB@ S1FBB@ S1FBB@ S1FBB@ S1FBB@ S1FBB@ S1FBB@ S1F
MBB@ S1FBB@ S1FBB@ S1FBB@#U_]@C_D[_P7_P!=+W_T@N:*3]@?_D[_ ,%_
M]=+W_P!(+FBO-QGQ_(]3 _ _4\AQ1BBBO2/+#%&*** #%:_@#P%J'Q4\?:%X
M7TI/,U3Q-J-OI-FH[S3RK$G_ (\XK(I58HP9258'((."*/0%YGZL?\% CI?Q
M$\%Z'J/@'Q?X+UZ^_9P^+VD^'=+AE^T#3_#&FR0VEE!%J#S0QJ8QJ&F[I&B,
MD>R1_F/-/^/_ ,/_ (E:M^UG\"=6T?6?$O@'Q1K'Q(U;6]0\)^(=1CU2Q\/R
MVY634=:T^[8),^C3VRRXCEV(02J*H8 ?E'N.UERVU_O#/#?7UHC_ '3;E+*V
MW9D'!V],?3VKCC@[))/:_3O_ ,'4[98R[;:WMU[?\#0^Z/\ @I/I$/Q+^+(\
M7>"?!EKXN^#6J?"I-4\!&SDET^#P98Q7,:WER\:,!)<07LLPDB?<I^VQY!*+
MCU#]@X'7/^"<'A7PSX>D&G_%?Q9_PG>G> =49@?LU_Y-E)/;Q X\NXN+-+F*
M.<,#$2V 2]?F2)7"!=[[0" NXX&>O'O0)67;AW&TY7#'Y3ZCTJI8:\%"^W]:
M_KW(CBK3<[;_ -?\-V/M[P5\)?BM\!/^"4VJ:_X>T+QUKLGQ=L+I;ZYM4N9M
M-\%^$[-F>Y5AGRHIKR56+C!*P1-G:6.?:OVC_A=I8_X)Y^*_@3#XFT:\\4?!
M/P%X;\7OX7MQ<F^TG4HY9[K6KB0M$(-LD.KH (Y7<>6-RCM^7!N9"FWS9=O0
MKO.#^%)YS[V;>^YAACN.6^IHEAVW=OK?;[OPT".)25DNEM_O_'4]F^,)S_P3
MJ^#?_8V>,_\ T3H5?IM^T[K6F_$WX.?M#WSM!#XD^$OP<C\-&)%_>7VF:KIN
MCZA;,3W\NYM=0'_;=:_(O7_BYJ7B/X-^%_ \]O8KI7A/4M3U2TF1&%Q+)?K:
M+,LA+%2JBSBV@*"-SY+9&.7,TA+?O)/F&&^8_,/0T3P_/9MVLW^+O^01Q')=
M)7NE^"M^9^H7[7WPMTI_^"=_C3X'0^)M'U#Q%\!?!?AKQ,_AFR%RVH:7>QF:
M36[B4M$L&)%U52!'*[#RP& / [OQM:^+_$7Q%^$'C#Q1J-YX3U35/BGX%L]4
MT>RU./4O!OCP1QP&VU70F=%EMS%&-L\48$6<@EV!9OR"\Y][-O?<X(8[CEL]
M<^M,1?+967Y6C^Z1_#SGCTYYXJ/J>EK_ (=[7_*YI]<5[\OX]KV_,_57XF_
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MACQ(N[X$Q6EXP\8:M\0O%NJ:]KVH76K:WK5U)>W][<OOFNYY&+.['U)/;@=
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M-[9_ QY[>XMY#'-;R+H1971ARK*0"".00#7+_P#!,O\ ;5\+_P#!6W]CC6O
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MOAZF*==1J+W.6]]$^:^SLWNNVFGH<WBC%%%<AZ08HQ110 8HQ110 8HQ110
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MRI58WC)6:[I]#U;XI?M?>)?B9\5_#_BSR+'2[CPNP;3K:(-)$AW!G+ECEM^
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HV9KFXT6:.*+=97"+EB,#+,H^I%%?T545SU<QG-W:1T4<#&FK)G__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
